COVID-19, Influenza A/B, Seasonal Influenza A subtyping, Influenza A/H5 and Influenza A/H7 Extraction Reagents
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Naval Medical Research Command (NMRC) intends to award a sole-source contract to Roche Diagnostics Corporation for COVID-19, Influenza A/B, Seasonal Influenza A subtyping, Influenza A/H5, and Influenza A/H7 extraction reagents. This is a Special Notice, not a request for competitive proposals, but interested parties may submit capability statements for government consideration by March 17, 2026.
Purpose & Justification
The NMRC's Naval Infectious Diseases Diagnostic Laboratory (NIDDL) requires these specific brand-name Roche supplies to meet Navy Expeditionary Medical Research requirements. The acquisition is justified under 10 U.S.C. 2304(c)(1) and FAR 13.106-1(b)(1), citing that the specified items are available only from Roche Diagnostics, and any changes would compromise diagnostic grade results. Market research confirmed no other sources have expressed interest.
Scope of Work
The requirement is for a drop shipment of Roche supplies, specifically reagents for 1,000 extraction reactions every three months, totaling 4,000 reactions across four shipments. Specific items include:
- MagNA Pure 96 Processing Cartridge (Cat. 06241603001): 12 units (3 per quarter)
- MagNA Pure Filter Tips (1000 ul) (Cat. 06241620001): 2 units (1 in Sep 2026, 1 in Mar 2027)
- MagNA Pure External Lysis Buffer (Cat. 06374913001): 32 units (8 per quarter)
- MagNA Pure 96 DNA and Viral NA SV Kit (Cat. 06543588001): 8 units (2 per quarter)
- MagNA Pure 96 System Fluid (External) (Cat. 06640729001): 12 units (3 per quarter)
Contract & Timeline
- Contract Type: Sole-Source (Special Notice)
- Set-Aside: None specified
- NAICS Code: 325413 (In-Vitro Diagnostic Substance Manufacturing)
- Procurement Method: FAR Part 12 (Commercial Items)
- Shipping Schedule: Quarterly shipments in June 2026, September 2026, December 2026, and March 2027.
- Capability Statement Due: March 17, 2026, at 7:00 PM ET.
- Published Date: March 3, 2026.
Additional Information
The Contracting Officer will determine the anticipated cost to be fair and reasonable. Future requirements will be synopsized, but NMRC currently has no plans to compete future contracts for these specific supplies. All contractors must be registered in the System for Award Management (SAM) and possess a Unique Entity Identification (UEI) number to be eligible for award.
Contact Information:
- Primary: SHAMAI CARTER (shamai.m.carter.civ@health.mil)
- Secondary: NATAKI JOHNSON LOVETT (nataki.s.johnsonlovett.civ@health.mil, 301-319-7303)
- General Contracts: usn.detrick.nmrc.mbx.mmd-contracts@health.mil